TABLE 5.
Summary of the immunohistochemical and EBER Profile of BI-ALCL Cases With LNI (n = 14)
| (+) Cases (n [%]) | |
|---|---|
| CD2 (n = 7) | 3 (42.9) |
| CD3 (n = 14) | 0 |
| CD4 (n = 13) | 11 (84.6) |
| CD5 (n = 11) | 2 (18) |
| CD7 (n = 9) | 0 |
| CD8 (n = 12) | 1 (8.3) |
| CD15 (n = 9) | 3 (33.3) |
| CD20 (n = 11) | 0 |
| CD30 (n=14) | 14 (100) |
| CD43 (n = 9) | 8 (88.9) |
| CD45 (n = 11) | 10 (90.9) |
| ALK (n=14) | 0 |
| EBER (n=9) | 0 |
| EMA (n = 7) | 5 (71.4) |
| PAX5 (n = 6) | 0 |
ALK indicates anaplastic lymphoma kinase; EBER, Epstein-Barr virus encoded RNA; EMA, epithelial membrane antigen; PAX5, paired-box protein 5.